Emerging immune checkpoint inhibitors for the treatment of oropharyngeal squamous cell carcinoma
Oropharyngeal Squamous Cell Carcinoma (OPSCC) is a challenging subtype of head and neck cancer that traditionally has been associated with poor prognosis and high morbidity due to the limitations of conventional treatments such as surgery, radiation, and chemotherapy. Immune checkpoint inhibitors ha...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Oral Oncology Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772906024004965 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Oropharyngeal Squamous Cell Carcinoma (OPSCC) is a challenging subtype of head and neck cancer that traditionally has been associated with poor prognosis and high morbidity due to the limitations of conventional treatments such as surgery, radiation, and chemotherapy. Immune checkpoint inhibitors have revolutionized OPSCC and other cancer therapies. ICIs that target the PD-1 and PD-L1 axis and CTLA-4 have altered cancer action by improving the immune system capacity to detect and kill cancer cells. This paper discusses the significant impact of ICIs like Pembrolizumab and Nivolumab, which have been approved for use in recurrent or metastatic OPSCC and have demonstrated remarkable efficacy in clinical trials. The integration of these therapies into clinical practice has been facilitated by the identification of biomarkers such as PD-L1 expression, which guides personalized treatment strategies. Moreover, ongoing research into combination therapies involving ICIs and other treatment modalities is poised which, leads for further improvement in patient outcomes. Despite the successes, challenges such as immune-related adverse events and resistance mechanisms remain, underscoring the need for continued innovation and exploration in the field. This review highlights the pivotal role of ICIs in redefining OPSCC treatment, offering new hope for sustained survival and improved quality of life. |
|---|---|
| ISSN: | 2772-9060 |